Overview
Shigellosis, also known as bacillary dysentery, is an acute infectious disease caused by bacteria of the genus Shigella. There are four species that cause human disease: Shigella dysenteriae (serogroup A), Shigella flexneri (serogroup B), Shigella boydii (serogroup C), and Shigella sonnei (serogroup D). The disease primarily affects the gastrointestinal system, specifically the colon and rectum, where the bacteria invade the intestinal epithelium, causing intense inflammation and mucosal destruction. Transmission occurs via the fecal-oral route, often through contaminated food, water, or direct person-to-person contact. The infectious dose is remarkably low, making it highly contagious. Key symptoms include watery or bloody diarrhea (dysentery), abdominal cramps, fever, nausea, vomiting, and tenesmus (painful straining during bowel movements). The illness typically begins 1 to 3 days after exposure and is usually self-limiting, resolving within 5 to 7 days. However, severe cases, particularly those caused by Shigella dysenteriae type 1, can lead to serious complications including hemolytic uremic syndrome (HUS), toxic megacolon, intestinal perforation, seizures (especially in young children), severe dehydration, and septicemia. Children under 5 years of age, elderly individuals, and immunocompromised patients are at greatest risk for severe disease and complications. Treatment focuses on rehydration therapy (oral or intravenous) to replace fluid and electrolyte losses. Antibiotic therapy is recommended for moderate to severe cases and can shorten the duration and severity of illness. Commonly used antibiotics include fluoroquinolones (such as ciprofloxacin), azithromycin, and third-generation cephalosporins, though antimicrobial resistance is an increasing global concern. Prevention strategies include proper hand hygiene, safe water supply, adequate sanitation, and food safety measures. No vaccine is currently widely available, though several candidates are in development.
Clinical phenotype terms— hover any for plain English:
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
10 eventsJohns Hopkins Bloomberg School of Public Health — PHASE2
GlaxoSmithKline — PHASE2
Inventprise Inc. — PHASE1
Eveliqure Biotechnologies GmbH — PHASE2
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — PHASE3
University of Oxford — PHASE1
LimmaTech Biologics AG — PHASE2
Leiden University Medical Center — PHASE1
Intralytix, Inc. — PHASE1, PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Shigellosis.
6 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Shigellosis.
Community
No community posts yet. Be the first to share your experience with Shigellosis.
Start the conversation →Latest news about Shigellosis
Disease timeline:
New recruiting trial: Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old
A new clinical trial is recruiting patients for Shigellosis
New recruiting trial: InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia
A new clinical trial is recruiting patients for Shigellosis
New recruiting trial: Shigella Sonnei 53G Human Infection Study in Kenyan Adults
A new clinical trial is recruiting patients for Shigellosis
New recruiting trial: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
A new clinical trial is recruiting patients for Shigellosis
New recruiting trial: The Impact of Shigellosis and Recommended Treatment in Children
A new clinical trial is recruiting patients for Shigellosis
New recruiting trial: First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
A new clinical trial is recruiting patients for Shigellosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Shigellosis
What is Shigellosis?
Shigellosis, also known as bacillary dysentery, is an acute infectious disease caused by bacteria of the genus Shigella. There are four species that cause human disease: Shigella dysenteriae (serogroup A), Shigella flexneri (serogroup B), Shigella boydii (serogroup C), and Shigella sonnei (serogroup D). The disease primarily affects the gastrointestinal system, specifically the colon and rectum, where the bacteria invade the intestinal epithelium, causing intense inflammation and mucosal destruction. Transmission occurs via the fecal-oral route, often through contaminated food, water, or direc
Are there clinical trials for Shigellosis?
Yes — 6 recruiting clinical trials are currently listed for Shigellosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Shigellosis?
25 specialists and care centers treating Shigellosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.